GENFLEET-B Surges Over 6% in Late Trading as Two Investigational Drugs Secure Slots at 2026 ASCO Conference

Stock News05-27

GENFLEET-B (02595) rose more than 6% in late trading. As of the time of writing, the stock was up 6.26%, trading at HK$34.28 with a turnover of HK$44.4851 million. The catalyst for the move was the company's announcement that clinical research findings for two of its investigational new drugs will be presented at the 2026 ASCO Annual Meeting. Specifically, data from the study of GFH375 monotherapy for KRAS G12D-mutated cholangiocarcinoma and colorectal cancer has been selected for an oral presentation. This research will mark the first time industry-specific clinical data on RAS inhibitor treatment for cholangiocarcinoma is released and will showcase the preliminary efficacy of GFH375 in treating these cancers. Additionally, clinical data for GFS202A, described as the world's first bispecific antibody for cachexia, will be presented for the first time in a poster session at the ASCO meeting. It is also noteworthy that on May 25th, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that GENFLEET has registered a Phase III clinical study. This randomized, controlled, open-label, multi-center trial will evaluate GFH375 compared to docetaxel in participants with locally advanced unresectable or metastatic non-small cell lung cancer harboring a KRAS G12D mutation who have failed prior standard therapies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153273037?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 15:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153273037","market":"sh","top_or_hot":-1,"title":"GENFLEET-B Surges Over 6% in Late Trading as Two Investigational Drugs Secure Slots at 2026 ASCO Conference","media":"Stock News","content":"<p>GENFLEET-B (02595) rose more than 6% in late trading. As of the time of writing, the stock was up 6.26%, trading at HK$34.28 with a turnover of HK$44.4851 million. The catalyst for the move was the company's announcement that clinical research findings for two of its investigational new drugs will be presented at the 2026 ASCO Annual Meeting. Specifically, data from the study of GFH375 monotherapy for KRAS G12D-mutated cholangiocarcinoma and colorectal cancer has been selected for an oral presentation. This research will mark the first time industry-specific clinical data on RAS inhibitor treatment for cholangiocarcinoma is released and will showcase the preliminary efficacy of GFH375 in treating these cancers. Additionally, clinical data for GFS202A, described as the world's first bispecific antibody for cachexia, will be presented for the first time in a poster session at the ASCO meeting. It is also noteworthy that on May 25th, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that GENFLEET has registered a Phase III clinical study. This randomized, controlled, open-label, multi-center trial will evaluate GFH375 compared to docetaxel in participants with locally advanced unresectable or metastatic non-small cell lung cancer harboring a KRAS G12D mutation who have failed prior standard therapies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENFLEET-B Surges Over 6% in Late Trading as Two Investigational Drugs Secure Slots at 2026 ASCO Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENFLEET-B Surges Over 6% in Late Trading as Two Investigational Drugs Secure Slots at 2026 ASCO Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-27 15:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENFLEET-B (02595) rose more than 6% in late trading. As of the time of writing, the stock was up 6.26%, trading at HK$34.28 with a turnover of HK$44.4851 million. The catalyst for the move was the company's announcement that clinical research findings for two of its investigational new drugs will be presented at the 2026 ASCO Annual Meeting. Specifically, data from the study of GFH375 monotherapy for KRAS G12D-mutated cholangiocarcinoma and colorectal cancer has been selected for an oral presentation. This research will mark the first time industry-specific clinical data on RAS inhibitor treatment for cholangiocarcinoma is released and will showcase the preliminary efficacy of GFH375 in treating these cancers. Additionally, clinical data for GFS202A, described as the world's first bispecific antibody for cachexia, will be presented for the first time in a poster session at the ASCO meeting. It is also noteworthy that on May 25th, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that GENFLEET has registered a Phase III clinical study. This randomized, controlled, open-label, multi-center trial will evaluate GFH375 compared to docetaxel in participants with locally advanced unresectable or metastatic non-small cell lung cancer harboring a KRAS G12D mutation who have failed prior standard therapies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1153273037","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153273037","pubTimestamp":1779866793,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENFLEET-B (02595) rose more than 6% in late trading. As of the time of writing, the stock was up 6.26%, trading at HK$34.28 with a turnover of HK$44.4851 million. The catalyst for the move was the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","09939":"开拓药业-B","VXUS":"国际股票ETF-Vanguard","BK1574":"生物医药B类股","02595":"劲方医药-B"},"translate_title":"GENFLEET-B尾盘飙升逾6%，两种研究药物在2026年ASCO会议上获得席位","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"VXUS":1,"02595":1},"content_text":"GENFLEET-B (02595) rose more than 6% in late trading. As of the time of writing, the stock was up 6.26%, trading at HK$34.28 with a turnover of HK$44.4851 million. The catalyst for the move was the company's announcement that clinical research findings for two of its investigational new drugs will be presented at the 2026 ASCO Annual Meeting. Specifically, data from the study of GFH375 monotherapy for KRAS G12D-mutated cholangiocarcinoma and colorectal cancer has been selected for an oral presentation. This research will mark the first time industry-specific clinical data on RAS inhibitor treatment for cholangiocarcinoma is released and will showcase the preliminary efficacy of GFH375 in treating these cancers. Additionally, clinical data for GFS202A, described as the world's first bispecific antibody for cachexia, will be presented for the first time in a poster session at the ASCO meeting. It is also noteworthy that on May 25th, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that GENFLEET has registered a Phase III clinical study. This randomized, controlled, open-label, multi-center trial will evaluate GFH375 compared to docetaxel in participants with locally advanced unresectable or metastatic non-small cell lung cancer harboring a KRAS G12D mutation who have failed prior standard therapies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153273037","isCrawlerRequest":true}